Costs incurred by patients undergoing advanced colorectal cancer therapy: A comparison of raltitrexed and fluorouracil plus folinic acid

PharmacoEconomics

Volumn 17, Issue 4, 2000, Pages 361-370

  Sculpher, Mark ^a   Palmer, Michael K ^b   Heyes, Anne ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; RALTITREXED;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG COST; DRUG INDUCED DISEASE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; TIME; TRAVEL;

EID: 0034055894     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017040-00006     Document Type: Article

References (18)

1. 1. Pritchard C. Trends in economic evaluation. OHE Briefing no. 36. London: Office of Health Econ, 1998
2. 2. Elixhauser A, Halpern M, Schmier J, et al. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care 1998; 36: MS1-MS9
3. 3. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: AGPS, 1995
4. 4. Canadian Coordinating Centre for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: CCHOTA, 1997
5. 5. Cocconi G, Cunningham D, Cutsem EV, et al. Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 2943-52
6. 6. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998; 77: 15-21
7. 7. Department of Transport. Transport statistics Great Britain. London: Government Statistical Service, 1997
8. 8. Office for National Statistics. Monthly digest of statistics. London: The Stationery Office, 1997
9. 9. Department of Health. Policy appraisal and health. London: Department of Health, 1995
10. 10. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York: Oxford University Press, 1996
11. 11. Drummond MF, Davies L. Economic analysis alongside clinical trials. Int J Technol Assess Health Care 1991; 7: 561-73
12. 12. Summerhayes M, Wanklyn SJ, Shakespeare RA, et al. Reduced pharmacy resource utilisation associated with raltitrexed treatment of advanced colorectal cancer. J Oncol Pharm Pract 1997; 3: 13-9
13. 13. Elliott R. An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancer. A comparison between raltitrexed ('Tomudex') and 5-fluorouracil plus folinic acid. J Oncol Pharm Pract 1996; 2: 186-90
14. 14. Kerr D, O'Connor KM. An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer. J Med Econ 1999; 2: 123-32
15. 15. Stephens RJ. Hopwood P, Johnston C, et al. The value of Quality of Life (QL) outcomes in comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in a multicentre randomised trial of metastatic colorectal cancer [abstract 2220]. Proc Am Soc Clin Oncol 1999; 18: 575a
16. 16. Young A, Topham C, Moore J, et al. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effect and administration attributes, Eur J Cancer Care 1999; 8: 154-61
17. 17. Manning WG, New house JP, Duan N, et al. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev 1987; 77: 251-77
18. 18. Torgerson DJ, Donaldson C, Reid DM. Private versus social opportunity cost of time: valuing time in the demand for health care. Health Econ 1994; 3: 149-55